Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of October 2020
Date of Report: October 13, 2020
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
Key Financial Metrics
The provided filing text does not contain specific financial data. This Form 6-K serves as a cover document for a press release (Exhibit 99.1) and does not include revenue, profit, cash flow, margins, debt, or liquidity figures within the text provided.
Material Changes
The filing text does not provide details on material changes versus prior periods. The document references a press release dated October 13, 2020, as the source of the reportable event, but the content of that release is not included in the input.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or descriptions of unusual items. These details are expected to be contained within the referenced Exhibit 99.1 (Press Release), which is not part of the provided text.
Investor Verification Checklist
- Review the full text of the Press Release dated October 13, 2020 (Exhibit 99.1) to understand the specific event triggering this filing.
- Verify if the press release contains updates on clinical trial progress, regulatory approvals, or partnership agreements, as these are typical for Innate Pharma S.A.
- Check subsequent filings (e.g., Form 20-F or quarterly reports) for the financial impact of the event reported in this 6-K.